A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout

Name: A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Creator: Vivli
Published: 2025-04-01 01:04:30
License: 暂无描述

DataCite Commons2025-04-01 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/00003350/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80 mg IR, respectively, in participants with gout.

提供机构：

Vivli

创建时间：

2019-03-06